5-hydroxy-6,8,11,14-eicosatetraenoic acid

Also Known As:

5-HETE; 5-hydroxy-6,8,11,14-eicosatetraenoic acid, (E,E,Z,Z)-isomer; 5-hydroxy-6,8,11,14-eicosatetraenoic acid, (E,Z,Z,Z)-(+-)-isomer; 5-hydroxy-6,8,11,14-eicosatetraenoic acid, (E,Z,Z,Z)-isomer; 5-hydroxy-6,8,11,14-eicosatetraenoic acid, (S)-(E,Z,Z,Z)-isomer; 5-hydroxy-6,8,11,14-eicosatetraenoic acid, R-(E,Z,Z,Z)-isomer; 5-hydroxyeicosatetraenoic acid; 6,8,11,14-eicosatetraenoic acid, 5-hydroxy-

Networked: 113 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - Unsaturated Fatty Acids: 8236
    - Eicosanoids: 3262
      - Arachidonic Acids: 122
        Hydroxyeicosatetraenoic Acids: 318
        5-hydroxy-6,8,11,14-eicosatetraenoic acid: 113
    - Essential Fatty Acids: 734
      - Arachidonic Acids: 122
        Hydroxyeicosatetraenoic Acids: 318
        5-hydroxy-6,8,11,14-eicosatetraenoic acid: 113

Experts

1.	Charles-Schoeman, Christina: 2 articles (11/2020 - 03/2018)
2.	Lee, Yuen Yin: 2 articles (11/2020 - 03/2018)
3.	Meriwether, David: 2 articles (11/2020 - 03/2018)
4.	Reddy, Srinivasa T: 2 articles (11/2020 - 03/2018)
5.	Shahbazian, Ani: 2 articles (11/2020 - 03/2018)
6.	Fenton, Jenifer I: 2 articles (01/2019 - 01/2017)
7.	Sordillo, Lorraine M: 2 articles (01/2019 - 01/2017)
8.	Newman, Robert A: 2 articles (10/2007 - 01/2005)
9.	Yang, Peiying: 2 articles (10/2007 - 01/2005)
10.	Erickson, Kent L: 2 articles (10/2005 - 02/2005)

Related Diseases

1.	Neoplasms (Cancer) 02/21/2005 - "Adding 5-HETE back to tumor cells reduced the t10, c12-CLA effect on both apoptosis and cell proliferation. " 01/01/1999 - "Exogenous 5-HETE can rescue these cancer cells. " 07/22/1988 - "We conclude that 5-HETE preferentially binds to endothelial cells and interferes with a specific receptor for tumor cells, whereas the other metabolites neither bind to cells nor affect cell adhesion." 07/22/1988 - "Platelet or PMN adhesion to endothelial cells was unaffected by the 5-HETE binding, but tumor cell adhesion was blocked by 40% (P less than 0.01). " 12/01/2013 - "The levels of 5-HETE were significantly greater in the TRAMP mice with metastasis than in the tumors in situ. "
2.	Neoplasm Metastasis (Metastasis) 12/01/2013 - "The levels of 5-HETE were significantly greater in the TRAMP mice with metastasis than in the tumors in situ. " 01/01/1994 - "Tumor leukotriene B4 and 5-hydroxyeicosatetraenoic acid levels were not reduced by dietary MO. The 18% FAO- and the 18% MO-fed mice showed similar relationships for the phospholipid fatty acids and prostaglandin E2, despite the lack of effect on metastasis. "
3.	Carcinogenesis 01/01/2021 - "Recent studies highlight the regulatory role of arachidonate lipoxygenase5 (Alox5) and its metabolite 5-hydroxyeicosatetraenoic acid (5-HETE) in cancer tumorigenesis and progression. " 10/01/2005 - "To delineate a possible mechanism of action for CLA, we have recently shown that the 5-lipoxygenase product, 5-hydroxyeicosatetraenoic acid (5-HETE), could play a role in CLA alteration of mammary tumorigenesis. " 03/01/2011 - "Inhibiting the production of the procarcinogenic eicosanoids prostaglandin E₂ (PGE₂) and 5-hydroxyeicosatetraenoic acid (5-HETE) can suppress carcinogenesis in rodents. " 05/01/2013 - "An overexpression of 5-LOX is accompanied with increase in 5-HETE, LTB4 production and high BrdU-LI with an increase of two key angiogenic factors for tumorigenesis; MMP-2 and VEGF. "
4.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 10/01/1987 - "Chemotaxis to suboptimal concentrations of LTB4 1.0 and 3.2 nmol/l, and 5-HETE 316 nmol/l, was markedly depressed in patients with chronic inflammatory bowel disease (CIBD). " 10/01/1987 - "Activation of neutrophil chemotaxis by leukotriene B4 and 5-hydroxyeicosatetraenoic acid in chronic inflammatory bowel disease." 08/01/1986 - "Release of leukotriene B4 and 5-hydroxyeicosatetraenoic acid during phagocytosis of artificial immune complexes by peripheral neutrophils in chronic inflammatory bowel disease." 03/01/1988 - "The lipoxygenase products of arachidonic acid (AA) metabolism, 5-hydroxyeicosatetraenoic acid (5-HETE) and leucotriene B4 (LTB4), are considered to have an important pathophysiological role in inflammatory bowel disease by stimulating the inflammatory response and by contributing to the diarrhoea. " 08/01/1986 - "The study suggests that complexes of the IgG-class previously demonstrated in chronic inflammatory bowel disease, particularly in Crohn's disease, may activate inflammatory neutrophils leading to release of significant amounts of the pro-inflammatory lipoxygenase metabolites, LTB4 and 5-HETE."
5.	Ulcerative Colitis 04/01/1988 - "As only 16% of all CIBD patients had elevated IFN-alpha levels as compared to 12% among the group of healthy volunteers, IFN-alpha does not seem to be of importance for the perpetuation of the inflammatory reaction in ulcerative colitis or Crohn's disease, and other factors may therefore be responsible for activation of the inflammatory cells to production of LTB4 and 5-HETE." 02/01/1982 - "In this study we demonstrate the sulfasalazine, at concentrations found in the stool of patients being treated for ulcerative colitis, blocks the synthesis of both 5-HETE and 5,12 diHETE by human neutrophils. " 08/01/1986 - "Release of approximately 9% of the intracellular pool of radiolabelled AA in phospholipids, and release of the pro-inflammatory mediators, leukotriene B4 (LTB4), constituting 1.8%, and 5-hydroxyeicosatetraenoic acid (5-HETE), constituting 2.9% of the total radioactivity released, were demonstrated in 15 patients with untreated Crohn's disease, 15 patients with ulcerative colitis, and in 15 healthy volunteers. "

Related Drugs and Biologics

1.	Leukotriene B4
2.	Lipoxygenase (Lipoxygenase-1)
3.	zileuton (Zyflo)
4.	Sulfasalazine (Azulfidine)
5.	Proteins (Proteins, Gene)
6.	Immunoglobulin G (IgG)
7.	15-hydroxy-5,8,11,13-eicosatetraenoic acid
8.	12-Hydroxy-5,8,10,14-eicosatetraenoic Acid
9.	Arachidonic Acid (Vitamin F)
10.	Leukotrienes

Related Therapies and Procedures

1.	Endovascular Procedures
2.	Tocolysis
3.	Therapeutics
4.	Drug Therapy (Chemotherapy)
5.	Aftercare (After-Treatment)